Aberdeen Group plc boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 9,760.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 50,981 shares of the biotechnology company's stock after purchasing an additional 50,464 shares during the quarter. Aberdeen Group plc owned about 0.12% of United Therapeutics worth $27,626,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Toth Financial Advisory Corp boosted its holdings in shares of United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics in the second quarter worth about $30,000. Gen Wealth Partners Inc bought a new stake in shares of United Therapeutics in the third quarter worth about $34,000. Caitlin John LLC purchased a new position in United Therapeutics during the 2nd quarter valued at approximately $37,000. Finally, PFS Partners LLC purchased a new position in United Therapeutics during the 3rd quarter valued at approximately $45,000. Institutional investors own 94.08% of the company's stock.
United Therapeutics Trading Down 0.6%
UTHR opened at $587.88 on Tuesday. United Therapeutics Corporation has a 12-month low of $455.63 and a 12-month high of $614.23. The business's fifty day simple moving average is $544.61 and its 200-day simple moving average is $536.98. The company has a market capitalization of $25.04 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 3.94 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the previous year, the firm earned $7.16 earnings per share. The business's revenue was up 4.1% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post 25.08 EPS for the current year.
United Therapeutics announced that its Board of Directors has authorized a share repurchase plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 8.3% of its shares through open market purchases. Share buyback plans are usually a sign that the company's leadership believes its shares are undervalued.
Insider Transactions at United Therapeutics
In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 412,238 shares of company stock worth $221,790,391. 8.60% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on UTHR. Leerink Partners boosted their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an "outperform" rating in a research report on Monday, October 19th. UBS Group set a $725.00 target price on shares of United Therapeutics in a report on Monday, October 19th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $697.00 to $725.00 and gave the company an "outperform" rating in a research report on Thursday, November 5th. HC Wainwright initiated coverage on shares of United Therapeutics in a report on Monday, November 9th. They issued a "buy" rating and a $660.00 price target for the company. Finally, BTIG Research increased their price target on shares of United Therapeutics from $728.00 to $768.00 and gave the company a "buy" rating in a report on Wednesday, November 4th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $676.40.
Check Out Our Latest Research Report on UTHR
United Therapeutics Company Profile
(
Free Report)
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
See Also
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.